Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(57.1%)
Phase 1
3(42.9%)
7Total
Phase 2(4)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT02461888Phase 2Completed

Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.

Role: collaborator

NCT02406222Phase 2Active Not Recruiting

Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)

Role: collaborator

NCT03188172Phase 2Active Not Recruiting

MUK Nine b: OPTIMUM Treatment Protocol

Role: collaborator

NCT01720875Phase 2Completed

Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)

Role: collaborator

NCT03015922Phase 1Unknown

Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma

Role: collaborator

NCT03191981Phase 1Withdrawn

Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma

Role: collaborator

NCT02145715Phase 1Unknown

Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma

Role: collaborator

All 7 trials loaded